Where I see patients (2)
Selected research
-
Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.
Blood
-
Molecular Plasticity Results in Oncofetal Reprogramming and Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia.
Blood cancer discovery
-
Therapy by omission: observation as a strategy in JMML.
Blood
Clinical trials
Venetoclax Basket Trial for High Risk Hematologic Malignancies
To determine the maximum tolerated dose (MTD of venetoclax given in combination with regimen-prescribed chemotherapy. The MTD is defined as the dose level associated with observed DLTs in <33% of enrolled subjects
Recruiting
More about this studyA Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Mye...
The incidence of dose limiting toxicities (DLTs) after the 1st course of therapy will be measured at different dose levels.
Recruiting
More about this studyContact me
Soothing the soul
Our music therapy program nurtures patients with bedside serenades, rap workshops and more.
Find out more
